| The EQ-5D-5L Valuation study in Thailand |
14 |
| Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs |
12 |
| Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT) |
12 |
| Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications |
10 |
| Health economic impact of liquid biopsies in cancer management |
9 |
| Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA |
9 |
| Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients |
8 |
| Cognitive behavior therapy for health anxiety: systematic review and meta-analysis of clinical efficacy and health economic outcomes |
7 |
| Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer |
7 |
| The cost-effectiveness of therapies to treat alcohol use disorders |
6 |
| Cost-effectiveness thresholds: methods for setting and examples from around the world |
6 |
| Management of dental caries among children: a look at the cost-effectiveness |
5 |
| Therapeutic applications and pharmacoeconomics of microneedle technology |
5 |
| Cost analysis of type 2 diabetes mellitus treatment in economically developed countries |
5 |
| Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review |
5 |
| Increased burden of disease and role of health economics: Asia-pacific region |
4 |
| Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries |
4 |
| The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia |
4 |
| Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications |
4 |
| Cost-effectiveness of somatostatin analogues in the treatment of acromegaly |
4 |
| Clinical efficacy and economic evaluation of online cognitive behavioral therapy for major depressive disorder: a systematic review and meta-analysis |
4 |
| The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel |
4 |
| A systematic review of health economic models and utility estimation methods in schizophrenia |
4 |
| Systematic review of healthcare costs related to mental health conditions among cancer survivors |
4 |
| Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC) |
4 |
| Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies |
3 |
| Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology |
3 |
| Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries |
3 |
| An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward? |
3 |
| Valuation of EQ-5D-5L health states: a comparison of seven Asian populations |
3 |
| Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand |
3 |
| Reviewing estimates of the burden in disability-adjusted life years (DALYs) of tick-borne encephalitis in Slovenia |
3 |
| Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry |
3 |
| Using multi-criteria decision analysis to appraise orphan drugs: a systematic review |
3 |
| Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies |
3 |
| Current health and economic burden of chronic diabetic osteomyelitis |
2 |
| Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study |
2 |
| The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France |
2 |
| A systematic review of the development and testing of additional dimensions for the EQ-5D descriptive system |
2 |
| A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs |
2 |
| Guidance toward the implementation of multicriteria decision analysis framework in developing countries |
2 |
| Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D |
2 |
| Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis |
2 |
| How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review |
2 |
| Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system |
2 |
| Cross-national drug price comparisons with economic weights in external reference pricing in Germany |
2 |
| Factors associated with physicians' decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients |
2 |
| Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease |
2 |
| Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France |
2 |
| Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations-A meeting report from ISPOR regional conference in Warsaw, 2019 |
2 |
